Table 1 Patients’ demographic characteristics
From: Acute versus chronic methotrexate poisoning; a cross-sectional study
No. | Age range (year) | Sex | Diagnosis of the basal illness | Dose of MTX | Period of MTX usage before the event | Type of event | Other drugs |
|---|---|---|---|---|---|---|---|
1a | 60–69 | Male | RA | Undetermined | Undetermined | LOC, skin and mucosal lesions | – |
2 | 2–9 | Male | Accidental | Undetermined | 1 day | Nausea and vomiting | – |
3 | 2–9 | Female | Accidental | Undetermined | 1 day | – | |
4 | 60–69 | Female | RA | 15 mg | More than 6 months | Mucosal lesions, nausea, vomiting, diarrhea, abdominal pain | Folic acid and hydroxychlorocin daily regularly |
5 | 60–69 | Female | RA | 70 mg/week instead of 10 mg/week | More than 6 months | Mucosal lesions | – |
6 | 40–49 | Male | Suicidal | 50 mg | 1 day | – | – |
7 | 20–29 | Female | Suicidal | 2.5× undetermined number | 1 day | Nausea and vomiting | – |
8 | 30–39 | Female | Psoriasis Suicidal (MDT) | 5 mg | Undetermined | Nausea and vomiting, drowsiness | Multi drug toxicity (MTX + Respiridone) |
9 | 50–59 | Female | RA | 2.5× undetermined number | 10 days | Mucosal lesion, diarrhea, GI bleeding | – |
10 | 10–19 | Female | Suicidal | 2.5× undetermined number | 1 day | Nausea and vomiting | – |
11 | 10–19 | Female | Suicidal | 87.5 mg | 1 day | Nausea and vomiting | – |
12 | 40–49 | Female | Suicidal | 125 mg | 1 day | – | – |
13 | 50–59 | Female | RA Suicidal | 150 mg | Undetermined | – | – |
14 | 10–19 | Male | Suicidal | 75 mg | 1 day | Nausea and vomiting | – |
15 | 70–79 | Female | RA | 70 mg/week instead of 10 mg/week | 11 days | Mucosal lesions | – |
16 | 50–59 | Female | Suicidal (MDT) | 50 mg | 1 day | – | MTX+ diazepam+ acetaminophen |
17 | 2–9 | Male | Accidental | 20 mg | 1 day | – | |
18 | 10–19 | Female | Suicidal | 12.5 mg | 1 day | – | MTX+ Prednisolone+ Azathioprine |
19 | 40–49 | Female | SLE | 50 mg/week instead of 15 mg/week | Undetermined | Mucosal lesions | – |
20 | 70–79 | Female | RA | 50 mg/week instead of 15 mg/week | More than 2 months | Mucosal lesions | – |
21 | 30–39 | Female | Psoriasis, SLE | 10 mg weekly | More than 1 year | Skin and mucosal lesions, GIB | Azathioprine |
22 | 30–39 | Female | SLE | 7.5 mg weekly | More than 6 months | Skin and mucosal lesions | Did not take the prescribed Folic acid |
23 | 50–59 | Female | RA | 7.5 mg/day instead to 7.5 mg/week | Undetermined | Mucosal lesions, nausea, vomiting, diarrhea | Did not take the prescribed Folic Acid |
24 | 50–59 | Female | RA | 50 mg weekly instead of 25 mg weekly | 1.5 month | Skin and mucosal lesions, abdominal pain, GIB | – |
25 | 40–49 | Female | RA | Amp 1000 mg instead of 50 mg weekly | 3 weeks | Skin and mucosal lesions, nausea and vomiting, abdominal pain | – |
26 | 70–79 | Female | RA | 17.5 mg instead of 2.5 mg weakly | More than 6 months | Mucosal lesions, nausea, vomiting, diarrhea, abdominal pain | – |
27 | 50–59 | Female | RA | 30 mg/week instead of 15 mg/week | More than 4 months | Skin and mucosal lesions | Cyclosporine |